These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 28945711)
1. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia . Brumbaugh Paradis H; Alter D; Llerandi D Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711 [TBL] [Abstract][Full Text] [Related]
2. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Crombie J; Davids MS Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339 [TBL] [Abstract][Full Text] [Related]
3. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001 [TBL] [Abstract][Full Text] [Related]
4. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240 [TBL] [Abstract][Full Text] [Related]
5. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525 [TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]
7. Venetoclax for the treatment of chronic lymphocytic leukemia. Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395 [TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635 [TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707 [No Abstract] [Full Text] [Related]
11. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies. Olin JL; Griffiths CL; Smith MB J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175 [TBL] [Abstract][Full Text] [Related]
13. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Gribben JG Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596 [TBL] [Abstract][Full Text] [Related]
14. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404 [TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922 [TBL] [Abstract][Full Text] [Related]
16. Venetoclax: A new wave in hematooncology. Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371 [TBL] [Abstract][Full Text] [Related]
17. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232 [TBL] [Abstract][Full Text] [Related]
19. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice. Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709 [TBL] [Abstract][Full Text] [Related]
20. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]